Polyhomeotic-like 3 (PHC3) is a ubiquitously expressed member of the polycomb gene family and part of the human polycomb complex hPRC-H. We found that in normal cells PHC3 associated with both hPRC-H complex components and with the transcription factor E2F6. In differentiating and confluent cells, PHC3 and E2F6 showed nuclear colocalization in a punctate pattern that resembled the binding of polycomb bodies to heterochromatin. This punctate pattern was not seen in proliferating cells suggesting that PHC3 may be part of an E2F6-polycomb complex that has been shown to occupy and silence target promoters in G 0 . Previous loss of heterozygosity (LoH) analyses had shown that the region containing PHC3 underwent frequent LoH in primary human osteosarcoma tumors. When we examined normal bone and human osteosarcoma tumors, we found loss of PHC3 expression in 36 of 56 osteosarcoma tumors. Sequence analysis revealed that PHC3 was mutated in nine of 15 primary osteosarcoma tumors. These findings suggest that loss of PHC3 may favor tumorigenesis by potentially disrupting the ability of cells to remain in G 0 .
Introduction
The Polycomb group genes (PcG) encode a diverse set of regulatory proteins that are involved in maintenance but not initiation of expression patterns that control development (Lund and van Lohuizen, 2004; Ringrose and Paro, 2004) . First identified in Drosophila (Lewis, 1978) , they have been found throughout higher eucaryotes. PcG complexes are responsible for longterm silencing of genes by altering chromatin structure through deacetylation of histone tails and by inhibiting ATP-dependent chromatin remodeling (Shao et al., 1999; van der Vlag and Otte, 1999) .
Studies have demonstrated that PcG proteins divide into two separate complexes (Ali and Bender, 2004; Cao and Zhang, 2004 ). The first complex, which includes homologues of the Drosophila esc and E(z) genes, has histone deacetylase activity (Sewalt et al., 1998; van Lohuizen et al., 1998) . The second PcG complex (dPRC-1 in Drosophila, mPRC1 in mice and hPRC-H in humans) contains homologues of the Drosophila Pc, Psc, Ph, RING and Scm genes (Franke et al., 1992; Alkema et al., 1997; Satijn et al., 1997; Shao et al., 1999) and can mediate silencing of target genes by interfering with SWI/Snf chromatin remodeling machinery, blocking transcriptional initiation and the recruitment of additional silencing activities (Shao et al., 1999; Francis et al., 2001; King et al., 2002; Levine et al., 2002; Dellino et al., 2004; Lavigne et al., 2004) .
In humans, there are three orthologues of the Drosophila Ph gene: PHC1, PHC2 and PHC3 Levine et al., 2002; Tonkin et al., 2002) . Database screening has shown that all three are evolutionarily conserved in vertebrates (Isono et al., 2005) . Each of the PHC genes encodes a (Cys)4-type zinc coordination domain (Deatrick et al., 1991) , and a sterile alpha motif (SAM) domain (Ponting, 1995) at the C-terminus. The SAM domain is common to several PcG genes and has been shown to be involved in protein-protein interactions (Kim et al., 2002; Isono et al., 2005) .
We set out to characterize the function of PHC3. As expected, we found that PHC3 interacted with members of the hPRC-H complex. We also found that PHC3 interacted with E2F6, possibly as part of a complex that occupies E2F-and Myc-responsive genes in G 0 (Ogawa et al., 2002) . PHC3 maps to a region of human chromosome 3q26 that has been found to undergo tumor-specific loss of heterozygosity (LoH) in human osteosarcomas (Kruzelock et al., 1997) . Because of its potential role in regulating gene expression during G 0 and its localization within a region of frequent loss, we hypothesized that PHC3 might be a tumor suppressor gene. We found that PHC3 expression was present in normal bone but absent in a majority of primary osteosarcoma tumors. When we examined DNA from primary osteosarcomas, we discovered somatic intragenic inactivating mutations. These findings were consistent with the role of PHC3 as a tumor suppressor gene in human osteosarcoma.
Results

PHC3 is part of the hPRC-H PcG complex but also binds E2F6
Co-immunoprecipitation analyses confirmed that Phc3 co-immunoprecipitated with proteins YY1 and M33 as previously reported (Levine et al., 2002) (Figure 1 ). We found that Phc3 also co-immunoprecipitated with E2F6 and Bmi1. As a negative control, Phc3 did not coimmunoprecipitate with CtBP or RB1 (data not shown), which have been shown to be part of a different PcG complex (Dahiya et al., 2001) , or with the unrelated protein Sox9. The data confirmed that PHC3 was part of the hPRC-H complex, which has previously been shown to contain PHC3, YY1 and M33 (Levine et al., 2002) and demonstrated that PHC3 may be part of an E2F6-containing PcG complex (Trimarchi et al., 2001; Ogawa et al., 2002) .
Subcellular localization of PHC3 is dependent on cell cycle stage PcG proteins form distinct nuclear foci called polycomb bodies that associate with heterochromatin (Saurin et al., 1998) . PHC1 and PHC2 are both found in these polycomb bodies . Analysis of PHC3 expression in human osteoblasts (NHOst) showed that PHC3 was diffusely localized in the nuclei of proliferating cells. Following induction of differentiation, a punctate pattern of nuclear distribution for PHC3 was observed as soon as day 2 following induction ( Figure 2 ). This punctate pattern continued throughout differentiation.
A similar pattern of punctate localization was observed in confluent cells. In nonconfluent cells, PHC3 was diffusely nuclear. As cells became confluent, PHC3 showed an increasingly punctate sublocalization (Figure 3) . The punctate pattern of localization of PHC3 was similar to that seen for heterochromatin-associating polycomb bodies.
PHC3 and E2F6 colocalize in confluent and differentiating cells To test whether PHC3 was part of an E2F6-containing complex, we examined the colocalization of PHC3 and E2F6. Human mesenchymal stem cell (hMSC) cultures were analysed for subcellular localization of PHC3 and E2F6 at 50% confluency and at >80% confluency. In cells that were 50% confluent, both PHC3 and E2F6 were expressed diffusely in the nucleus. In contrast, when the cells were >80% confluent, PHC3 and E2F6 were colocalized in the nucleus in a punctate pattern (Figure 4 ). Similar patterns of colocalization were seen when the cells were induced to differentiate along the osteogenic lineage (data not shown). This punctate pattern of colocalization was similar to that seen for PHC3 alone in differentiating and confluent cells (Figures 2 and 3 ). This strongly suggested that PHC3 and E2F6 were part of a G 0 -specific DNA-binding complex (Ogawa et al., 2002) .
Absence of expression of PHC3 in primary osteosarcoma tumors If PHC3 was part of an E2F6 G 0 -regulating complex, then loss of PHC3 function from this complex might affect cells entering or remaining in G 0 , favoring tumorigenesis. Significantly, PHC3 maps to a region of human chromosome 3q26.2 that was shown to undergo frequent LoH in osteosarcomas (Kruzelock et al., 1997) . As LoH is frequently associated with homozygous inactivating mutations that lead to loss of Figure 1 Co-immunoprecipitation analysis. Total protein lysates from adult mouse bone were immunoprecipitated with antibody against Phc3, followed by Western blot with a second antibody. Western blotting with antibodies against Bmi1, M33, YY1 and E2F6 detected the presence of these proteins complexed with Phc3. No association was detected using an antibody against Sox9. IP, antibody used for immunoprecipitation; WB, antibody used for Western blot detection; TL, total protein lysate; -, negative control.
PHC3 acts as a tumor suppressor gene in osteosarcoma AM Deshpande et al expression of tumor suppressor genes (Haber and Harlow, 1997) , we tested for PHC3 and E2F6 expression in human osteosarcoma tumor tissue arrays. Fifty-six informative cases of osteosarcoma were examined. As a positive control, we examined coexpression in a dpc12.5 embryonic mouse. Our analysis showed that Phc3 was expressed in the cells of the embryonic mouse skeleton and PHC3 expression was absent in 36 of 56 (64%) osteosarcoma tumors. E2F6 was present in all of the tumors and the developing mouse skeleton. Examples of the analysis are shown in Figure 5 .
Somatic intragenic mutations disrupt PHC3 in human primary osteosarcoma tumors As PHC3 expression was absent in a majority of osteosarcoma tumors, we sequenced matched sets of normal and tumor DNAs from 15 patients with Figure 2 Subcellular localization of PHC3 in differentiating NHOst cells. Cells seeded at low density were induced to terminally differentiate and PHC3 expression was analyzed at 0, 2, 5 and 7 days post-induction. Analyses of uninduced cells were performed at the same times. Induction of differentiation resulted in a shift to a punctate pattern of PHC3 expression with punctate staining becoming more pronounced through day 7 (left panels). Punctate PHC3 expression was not seen in uninduced cells until confluency was achieved at approximately day 7 (right panels). At day 13 postinduction, induced and uninduced NHOst cells were stained using Alizarin Red to demonstrate mineralization, a function of terminal osteoblast differentiation ( Â 100 magnification). Figure 3 Immunofluorescence analysis of confluent NHOst cells. Cells were analysed for PHC3 localization at 50% confluency and at >80% confluency as well as on days 2, 5 and 7 following confluency. PHC3 was localized in the nucleus in a punctate expression pattern in the confluent cells.
PHC3 acts as a tumor suppressor gene in osteosarcoma AM Deshpande et al osteosarcoma, to see if mutations could be found in the tumors. In one tumor sample, PCR amplification of exon 2 revealed two bands (Figure 6a ). We sequenced the PCR fragments from this tumor. The larger fragment proved to be owing to a tandem duplication that resulted in a 196 bp insertion into the coding region of exon 2 (Figure 6b ). The insertion was not present in the matched normal DNA sample from the same patient, suggesting that the mutation arose somatically in the tumor. It is not clear whether the mutation was actually heterozygous in the tumor or a result of contamination of the tumor sample with normal cells during DNA extraction. Sequence analysis of the remaining 14 samples revealed that seven tumors had homozygous 1-4 bp insertions/deletions that caused frameshift mutations (Figure 6c ). The most proximal mutation was a 1 bp deletion in codon 2 that would eliminate the entire protein. The most distal mutation was a 4 bp deletion at codon 799 that would eliminate the SAM domain of the protein. None of the mutations were found in the matched normal DNA, suggesting that all had arisen somatically in the tumors.
One tumor had a C-to T-substitution that led to a TAG stop codon at codon 419 (Figure 6c ). This mutation appeared to be heterozygous in the tumor. The mutation was not found in the DNA from the matched normal sample, suggesting that the mutation arose somatically in the tumor. As in the first tumor, it is not clear whether the wild-type allele was actually present in the tumor or whether the presence of the wildtype allele was due to contaminating normal cells.
A map of the mutations in relation to the conserved domains of the protein is shown in Figure 6d . The mutations showed no evidence for hot spots, suggesting that the mutations likely inactivated the gene product rather than activated a novel function. This is consistent with the concept that loss of function is the critical event for tumor suppressor genes in tumorigenesis (Haber and Harlow, 1997) .
Discussion
In mice, Phc1 has a critical role in mediating PcGdependent bridging of distant chromatin templates (Lavigne et al., 2004) . Co-immunoprecipitation of PHC1 and PHC2 proteins from HeLa and U2OS cell extracts suggests that the polymerization of SAM domains of the PHC proteins may be involved in mediating PcG-dependent silencing through higherorder chromatin structures Levine et al., 2002) .
During the initiation of silencing by the PcG complexes, specific subunits of the PRC1 complex must interact with chromatin to recruit the free nucleosome arrays. Protein interactions have been shown to be mediated through the SAM domain (Ph) and the RING domain (RING and Bmi1), which may also play a critical role in recruitment (Levine et al., 2002; Lavigne et al., 2004) . Studies have shown that the PRC1 complex does not significantly alter nucleosomal position or access of nucleases to the nucleosomal arrays (Dellino et al., 2004; Lavigne et al., 2004) . This suggests that the PRC1 complex can inhibit chromatin remodeling by blocking interaction with SWI/Snf without making the template inaccessible. This may be important, as it would permit cells to reactivate silenced genes if needed.
The PHC orthologues are not completely interchangeable, as PHC1 has a more restricted tissue distribution than either PHC2 or PHC3 (Tonkin et al., 2002; Isono et al., 2005) . Moreover, mutations in PHC1 or PHC2 are not equivalent, as the double mutant Phc1/Phc2 has a synergistic effect (Takihara et al., 1997; Isono et al., 2005) . Thus, PHC3 either cannot substitute for the other PHC proteins or mutant forms of PHC1/PHC2 may affect the oligomerization of PRC1 complexes containing PHC3 or PHC3 may not be present in sufficient quantities to allow oligomerization of PRC1 complexes on DNA (Isono et al., 2005) .
PHC3 is part of an hPRC-H complex that associates with E2F6
We found that in addition to members of the hPRC-H complex, PHC3 co-immunoprecipitated with E2F6. This suggested that the PHC3 might be part of an E2F6-containing complex that contributes to long-term silencing of genes in quiescent cells (Ogawa et al., 2002) . The idea that PHC3 may play a role in regulation of transcription silencing during G 0 was supported by localization analysis. In proliferating cells PHC3 had a diffuse nuclear localization. During differentiation, Figure 4 Co-immunofluorescence analysis of PHC3 and E2F6 in proliferating and confluent cells. hMSC cells were analysed for PHC3 and E2F6 localization by immunofluorescence at 50% confluency and >80% confluency. At 50% confluency (proliferating cells), both PHC3 and E2F6 are diffusely nuclear. In the >80% confluent cells, both PHC3 (red) and E2F6 (green) colocalize (yellow) in the nucleus in a punctate pattern.
PHC3 acts as a tumor suppressor gene in osteosarcoma AM Deshpande et al Figure 5 Immunofluorescent analysis of PHC3 expression. Representative examples of normal (hMSC and dpc12.5 mouse skeleton) and primary osteosarcoma tumors (OS-1 through OS-6) were tested for PHC3 (red) and E2F6 (green) expression by immunofluorescence imaging. Hematoxylin and eosin (H&E) stains of serial sections from the same mouse skeleton and tumors are also shown. Positive PHC3 staining can be seen in the hMSC cell line and the developing mouse skeleton vertebrae. Osteosarcoma tumors OS-1 through OS-4 are examples of PHC3 À tumors whereas OS-5 and OS-6 are examples of PHC3 þ tumors. All H&E-stained photos were taken at Â 100. NC, negative controls where no primary antibody was used for staining mouse skeleton. PHC3 acts as a tumor suppressor gene in osteosarcoma AM Deshpande et al PHC3 shifted to a punctate nuclear localization. Similar results were observed when the cells were allowed to become confluent. These data were consistent with localization of PHC3 to the polycomb bodies during G 0 .
Punctate colocalization of PHC3 and E2F6 in confluent and/or differentiating cells supported the model of a PHC3-containing hPRC-H complex binding DNA during G 0 ; our data suggested by extension that this complex was also the E2F6-containing complex.
PHC3 acts as a tumor suppressor gene in osteosarcoma AM Deshpande et al
The role of PHC3 in the complex may be to regulate binding to the DNA or compaction of the nucleosome arrays. As with other PHC proteins, it is possible that the SAM or (Cys)4-type zinc coordination domains may play an important functional role in PHC3. Loss of PHC3 function could lead to inability to maintain longterm G 0 silencing mediated by the complex and allow cells to continue proliferating.
PHC3 in osteosarcoma tumorigenesis
Thus, several lines of data suggest that loss of PHC3 function would favor tumorigenesis. First, other PcG genes have been implicated in tumorigenesis (Leung et al., 2004; Pasini et al., 2004; Gil et al., 2005; Raaphorst, 2005; Nowak et al., 2006) . PcG complexes have been shown to regulate control of cellular proliferation and loss of this control would favor tumorigenesis (Dahiya et al., 2001; Pasini et al., 2004; Bracken et al., 2006) . Second, the discovery that the E2F6 complex present in HeLa cells cannot occupy target genes (Ogawa et al., 2002) suggests that the E2F6-containing complex is incomplete in some form. PHC3 was missing from the HeLa cell E2F6-containing complex suggesting that in its absence the complex cannot bind DNA or regulate transcription.
The discovery that PHC3 lies within a region of human chromosome 3q26.2 shown to undergo LoH at high frequency in osteosarcomas (Kruzelock et al., 1997) suggests PHC3 as a possible tumor suppressor. Expression analysis showed PHC3 was present in cultured hMSC, osteoblasts and embryonic mouse skeleton but absent in a significant fraction of osteosarcoma tumors.
Finally, tumor suppressor genes characteristically have homozygous intragenic tumor-specific inactivating mutations that result in an absence of functional protein (Haber and Harlow, 1997) . When we examined DNA from matched tumor and normal tissues, we found somatic mutations in nine of the osteosarcoma tumors. These frameshift and nonsense mutations showed no evidence of clustering, suggesting that the mutations led to loss of function rather than alteration in function.
When taken together, these data are consistent with PHC3 as a tumor suppressor gene. In conjunction with the loss of checkpoints controlled by the RB1 and p53 pathways in osteosarcoma (Wang, 2005) , the end result would be loss of the ability of the cell to exit cell cycle or remain in quiescence, thus strongly promoting tumorigenesis.
Materials and methods
Patient materials and cell lines
NHOst and hMSC (Cambrex Corp., East Rutherford, NJ, USA) were grown according to the manufacturer's recommendations.
All patient tumor and normal DNA samples used in this study were collected with Institutional Review Boardapproved informed consent as part of Phase III trials conducted by the Childrens Oncology Group (Arcadia, CA, USA). All samples were completely anonymous with no patient identifiers. DNA was isolated from tumors and blood and/or adjacent normal bone using the Wizard Genomic DNA purification kit (Promega Corp., Madison, WI, USA). For immunofluorescent analysis, commercial tumor microarrays (HistoArrays, Imgenex Corp., San Diego, CA, USA) were used.
PHC3 antibody
A peptide sequence (ERELRDVRIRKMPENSD) found in both human and mouse PHC3, but not PHC1 or PHC2, was conjugated to KLH (Research Genetics/Invitrogen, Carlsbad, CA, USA) and used to generate mouse monoclonal antibodies (Hybridoma Center for Agriculture and Biological Sciences (HYCABS), Oklahoma State University (http://www.ento. okstate.edu/hycabs/)). The specificity of the anti-PHC3 antibody was confirmed by Western analysis. The antibody detected a single protein band of approximately 110-115 kDa, which is the same size as previously described (Levine et al., 2002) (data not shown).
Co-immunoprecipitation
Proteins were extracted from snap-frozen mouse femurs and immunoprecipitation was performed as described previously (Harlow and Lane, 1988) . Western analysis was carried out using the appropriate second antibody as described previously (Harlow and Lane, 1988) . The antibodies used were Bmi1 (H95), CtBP (H440), E2F6 (E20), RB1 (IF8), YY1 (H10) and Sox9 (H90) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Immunofluorescence and colocalization analysis For confluency analysis, cells were plated on chamber slides at 50% confluency. The cells were fed with growth media (Cambrex Corp., East Rutherford, NJ, USA) following the manufacturer's protocol. The cells became >80% confluent within 48 h. Confluent cultures continued to be fed with appropriate growth media for 7 days. For analysis of differentiating cells, cells were grown on chamber slides and induced to differentiate by feeding with osteogenic differentiation media (Cambrex Corp., East Rutherford, NJ, USA) following the manufacturer's protocol.
Immunofluorescence analysis was performed as described previously (Harlow and Lane, 1988 ) using our mouse monoclonal antibody to PHC3. Goat polyclonal antibody to E2F6 (E-20, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used for colocalization assays. All immunofluorescently labeled samples were viewed on a BX-60 microscope (Olympus America Inc., Melville, NY, USA) and images captured with a digital cooled-CCD camera (Hamamatsu Corp., Bridgewater, NJ, USA) and OpenLab image analysis software (Improvision Inc., Lexington, MA, USA). Colocalization was determined using the OpenLab Colocalization software module. All photographs were taken at Â 200 magnification, unless otherwise noted.
To show terminal differentiation of the osteoblast lineage, cells were stained with Alizarin Red (Sigma-Aldrich, St Louis, MO, USA) as recommended by the manufacturer.
Tumor microarray analysis Analysis of tumor arrays was performed as previously described (Harlow and Lane, 1988) except that deparaffinized array slides were first treated with 4 N HCl for 10 min before incubation with mouse monoclonal antibody to PHC3 and goat antibody to E2F6 followed by incubation with Alexafluor-labeled secondary antibodies (anti-mouse IgG and anti-goat IgG, Invitrogen/Molecular Probes Inc., Eugene, OR, USA) for detection. Five-micrometer-thick sections of paraffin-embedded 12.5 dpc mouse embryo sections were also used as positive controls for PHC3 and E2F6 expression.
Samples were viewed and images captured as described above. Samples with less than 50 tumor cells in the microscope field were excluded from the analyses. Fluorescent signal intensities for both PHC3 and E2F6 were compared to positive (mouse embryo) control using OpenLab software. Loss of expression of PHC3 had occurred if the fluorescent intensity of PHC3 in the tumor sample was p15% of the fluorescent intensity of PHC3 in the positive control and if the fluorescent intensity of E2F6 in the tumor sample was X85% of the fluorescent intensity of E2F6 in the positive control.
Sequence analysis
Primers for each exon were designed from flanking introns of the PHC3 gene (Supplementary Table 1 ). Each exon was amplified by PCR and the product gel-purified using Sephadex-G50 columns. DNA sequencing was performed by the University of Connecticut Health Center sequencing core. Comparative analysis of the sequences was performed using CodonCode Aligner (Codon Code Corp., Dedham, MA, USA).
